Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

$36.38

0.72 (2.02%)

, ALNY

Alnylam

$70.30

1.73 (2.52%)

17:26
10/05/16
10/05
17:26
10/05/16
17:26

Ionis Pharmaceuticals down 5.2% after Alnylam drug development halt

IONS

Ionis Pharmaceuticals

$36.38

0.72 (2.02%)

ALNY

Alnylam

$70.30

1.73 (2.52%)

  • 07

    Oct

  • 14

    Oct

  • 06

    Nov

IONS Ionis Pharmaceuticals
$36.38

0.72 (2.02%)

10/04/16
RBCM
10/04/16
NO CHANGE
Target $375
RBCM
Outperform
Biogen could rise $20 or more per share on SMA success, says RBC Capital
RBC Capital analyst Michael Yee expects the first presentation of data from Biogen's (BIIB) Phase III ENDEAR trial studying nusinersen, an investigational treatment for spinal muscular atrophy, or SMA, this week, potentially during the late breaker session at the WMS Congress on October 8. Biogen and partner Ionis Pharmaceuticals (IONS) already announced in August that the study in Type I infants hit the interim analysis and stopped early for positive data. The much larger opportunity in older children has data expected to read out in Spring 2017, noted Yee, who thinks Biogen can have upside from $10 to over $20 per share based on its SMA opportunity. Yee keeps an Outperform rating and $375 price target on Biogen shares.
09/28/16
JANY
09/28/16
INITIATION
Target $47
JANY
Buy
Ionis Pharmaceuticals initiated with a Buy at Janney Capital
Janney Capital analyst Roy Buchanan initiated Ionis Pharmaceuticals with a Buy and a $47 fair value estimate. Buchanan believes the late stage pipeline, including wholly-owned volanesorsen, and the base technology can add meaningful value to Ionis. 1H 2017 is particularly rich with 3 phase 3 readouts, with potential for another early, interim look at SMA.
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
09/26/16
PIPR
09/26/16
NO CHANGE
Target $46
PIPR
Overweight
Ionis nusinersen program advancing faster than expected, says Piper Jaffray
After Biogen (BIIB) and Ionis (IONS) announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. FDA for the approval of nusinersen, an investigational treatment for spinal muscular atrophy, Piper Jaffray analyst Joshua Schimmer said that the nusinersen program is advancing faster than many have expected. Nusinersen may launch before AveXis (AVXS) starts its next Phase 3 trial, added Schimmer, who believes nusinersen will emerge as a multi-billion dollar product. The analyst keeps an Overweight rating and $46 price target on Ionis shares.
ALNY Alnylam
$70.30

1.73 (2.52%)

09/28/16
JANY
09/28/16
INITIATION
Target $74
JANY
Neutral
Alnylam initiated with a Neutral at Janney Capital
Janney Capital analyst Roy Buchanan initiated Alnylam with a Neutral and a $74 fair value estimate. The analyst is not confident about the outcome for the pivotal study for patisiran in transthyretin familial amyloid neuropathy, expected in about 12 months, and give patisiran a 50% chance of success.
09/15/16
FBRC
09/15/16
INITIATION
Target $82
FBRC
Underperform
FBR calls Alexion overvalued, starts shares at Underperform
FBR Capital analyst Christopher James initiated coverage of Alexion Pharmaceuticals (ALXN) with an Underperform rating and $82 price target. The biotech focused on patients with ultra-rare disorders closed yesterday up $2.63 to $129.42. Alexion shares are overpriced as the company is facing a competitive near-term landscape, particularly from Alnylam's (ALNY) ALN-CC5, James tells investors in a research note. Further, near-term expansion into additional indications will be challenging given the recent failed study with eculizumab in refractory generalized myasthenia gravis, the analyst contends. He also sees possible pricing pressures from biosimilars, including an Amgen (AMGN) biosimilar product in development. James this morning also initiated Achillion Pharmaceuticals (ACHN) and Arena Pharmaceuticals (ARNA) with Outperform ratings.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
08/22/16
WEDB
08/22/16
NO CHANGE
WEDB
Intellia Therapeutics data positive, says Wedbush
Wedbush analyst David Nierengarten says that additional data on Intella's (NTLA) TTR program in mice was "meaningful" and indicates that the program compares favorably with competing products. The analyst says that competing programs, including those of Alnylam (ALNY) and Ionis (IONS) have shown "only a transient benefit." He reiterates a $38 price target and Outperform rating on Intella.

TODAY'S FREE FLY STORIES

AUDC

AudioCodes

$6.62

0.11 (1.69%)

05:51
04/26/17
04/26
05:51
04/26/17
05:51
Earnings
AudioCodes reports Q1 EPS 7c, consensus 7c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CREE

Cree

$24.82

0.07 (0.28%)

05:51
04/26/17
04/26
05:51
04/26/17
05:51
Downgrade
Cree rating change  »

Cree downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

BIG

Big Lots

$49.57

-0.36 (-0.72%)

05:49
04/26/17
04/26
05:49
04/26/17
05:49
Upgrade
Big Lots rating change  »

Big Lots upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTI

Apptio

$12.80

0.09 (0.71%)

05:48
04/26/17
04/26
05:48
04/26/17
05:48
Upgrade
Apptio rating change  »

Apptio upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

NORD

Nord Anglia

$32.82

5.2 (18.83%)

05:46
04/26/17
04/26
05:46
04/26/17
05:46
Downgrade
Nord Anglia rating change  »

Nord Anglia downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

AKS

AK Steel

$6.40

-0.72 (-10.11%)

05:44
04/26/17
04/26
05:44
04/26/17
05:44
Recommendations
AK Steel analyst commentary  »

AK Steel selloff a buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

CMG

Chipotle

$471.76

2.97 (0.63%)

05:43
04/26/17
04/26
05:43
04/26/17
05:43
Downgrade
Chipotle rating change  »

Chipotle downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHOP

Shopify

$76.65

0.82 (1.08%)

05:43
04/26/17
04/26
05:43
04/26/17
05:43
Downgrade
Shopify rating change  »

Shopify downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 24

    May

ALGT

Allegiant Travel

$163.85

-1.2 (-0.73%)

05:40
04/26/17
04/26
05:40
04/26/17
05:40
Downgrade
Allegiant Travel rating change  »

Allegiant Travel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DYN

Dynegy

$6.19

-0.11 (-1.75%)

05:37
04/26/17
04/26
05:37
04/26/17
05:37
Upgrade
Dynegy rating change  »

Dynegy upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    May

RSPP

RSP Permian

$38.69

1.32 (3.53%)

05:33
04/26/17
04/26
05:33
04/26/17
05:33
Initiation
RSP Permian initiated  »

RSP Permian reinstated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

CPE

Callon Petroleum

$12.24

0.39 (3.29%)

05:32
04/26/17
04/26
05:32
04/26/17
05:32
Initiation
Callon Petroleum initiated  »

Callon Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

LOGI

Logitech

$31.79

0.99 (3.21%)

05:32
04/26/17
04/26
05:32
04/26/17
05:32
Earnings
Logitech backs FY18 outlook of high single-digit retail sales growth »

Logitech confirmed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

FSNN

Fusion Telecommunications

$1.43

0.01 (0.70%)

05:31
04/26/17
04/26
05:31
04/26/17
05:31
Initiation
Fusion Telecommunications initiated  »

Fusion Telecommunications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

LOGI

Logitech

$31.79

0.99 (3.21%)

05:30
04/26/17
04/26
05:30
04/26/17
05:30
Earnings
Logitech reports Q4 EPS 15c, consensus 17c »

Reports Q4 revenue $496M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

SKYAY

Sky

$50.26

0.05 (0.10%)

05:29
04/26/17
04/26
05:29
04/26/17
05:29
Upgrade
Sky rating change  »

Sky upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.56

0.91 (1.70%)

05:26
04/26/17
04/26
05:26
04/26/17
05:26
Hot Stocks
Wells Fargo issues statement in response to CA State Treasurer John Chiang »

"Notwithstanding the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    May

  • 31

    May

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

KLRE

KLR Energy Acquisition

$10.55

0.1384 (1.33%)

04:55
04/26/17
04/26
04:55
04/26/17
04:55
Conference/Events
KLR Energy Acquisition to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

IONS

Ionis Pharmaceuticals

$47.88

2.14 (4.68%)

04:55
04/26/17
04/26
04:55
04/26/17
04:55
Conference/Events
Ionis Pharmaceuticals management to meet with Needham »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 24

    May

ADMS

Adamas Pharmaceuticals

$16.36

0.51 (3.22%)

, AVXS

AveXis

$78.74

-0.44 (-0.56%)

04:55
04/26/17
04/26
04:55
04/26/17
04:55
Conference/Events
American Academy of Neurology »

69th Annual Meeting of…

ADMS

Adamas Pharmaceuticals

$16.36

0.51 (3.22%)

AVXS

AveXis

$78.74

-0.44 (-0.56%)

CATB

Catabasis Pharmaceuticals

$1.48

-0.02 (-1.33%)

MNOV

MediciNova

$5.57

0.14 (2.58%)

IONS

Ionis Pharmaceuticals

$47.88

2.14 (4.68%)

FLKS

Flex Pharma

$3.07

0.01 (0.33%)

TGTX

TG Therapeutics

$12.00

1.6 (15.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 24

    May

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 24

    Aug

ATEC

Alphatec

$1.98

0.02 (1.02%)

, CAE

CAE

$15.39

0.01 (0.07%)

04:55
04/26/17
04/26
04:55
04/26/17
04:55
Conference/Events
American Association of Neurological Surgeons to hold annual meeting »

2017 AANS Annual…

ATEC

Alphatec

$1.98

0.02 (1.02%)

CAE

CAE

$15.39

0.01 (0.07%)

EDGE

Edge Therapeutics

$10.72

1.07 (11.09%)

MDT

Medtronic

$81.76

1.11 (1.38%)

NUVA

NuVasive

$76.94

0.59 (0.77%)

SYK

Stryker

$135.59

1.14 (0.85%)

VRTX

Vertex

$117.27

-0.39 (-0.33%)

SYNA

Synaptics

$52.54

0.84 (1.62%)

NVIV

InVivo Therapeutics

$4.00

0.05 (1.27%)

LMAT

LeMaitre

$25.63

0.17 (0.67%)

MZOR

Mazor Robotics

$34.74

0.98 (2.90%)

OFIX

Orthofix

$39.28

0.19 (0.49%)

SSNLF

Samsung

SIEGY

Siemens

$72.70

0.615 (0.85%)

SNE

Sony

$33.65

-0.17 (-0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 03

    May

  • 18

    May

  • 24

    May

  • 25

    May

  • 31

    May

  • 06

    Jun

ABUS

Arbutus Biopharma

$3.35

0.05 (1.52%)

04:55
04/26/17
04/26
04:55
04/26/17
04:55
Conference/Events
Arbutus Biopharma management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

SXL

Sunoco Logistics

$24.35

0.64 (2.70%)

, ETP

Energy Transfer Partners

$36.42

0.98 (2.77%)

04:55
04/26/17
04/26
04:55
04/26/17
04:55
Conference/Events
Energy Transfer Partners to host special shareholder meeting »

Special Shareholder…

SXL

Sunoco Logistics

$24.35

0.64 (2.70%)

ETP

Energy Transfer Partners

$36.42

0.98 (2.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 23

    May

TIG

TiGenix

$16.36

0.08 (0.49%)

04:55
04/26/17
04/26
04:55
04/26/17
04:55
Conference/Events
TiGenix management to meet with Canaccord »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

MTSI

MACOM

$53.84

-0.17 (-0.31%)

, SBGI

Sinclair Broadcast

$39.30

-0.15 (-0.38%)

04:55
04/26/17
04/26
04:55
04/26/17
04:55
Conference/Events
National Association of Broadcasters to hold a conference »

NAB Show 2017 is being…

MTSI

MACOM

$53.84

-0.17 (-0.31%)

SBGI

Sinclair Broadcast

$39.30

-0.15 (-0.38%)

NXST

Nexstar

$68.90

0.3 (0.44%)

TRCO

Tribune Media

$36.55

-0.08 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 09

    May

  • 22

    May

  • 23

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.